FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2124542765> ?p ?o ?g. }

• W2124542765 endingPage "884" @default.
• W2124542765 startingPage "879" @default.
• W2124542765 abstract "Background. X-linked hypophosphatemia (XLH) is characterized clinically by rickets and growth retardation. Conventional treatment of XLH with oral phosphate and vitamin D fails to normalize linear growth. Objective. To determine the benefit and the potential side effects of recombinant human growth hormone (rhGH) therapy in patients with XLH. Design and Methods. A randomized, double-blind, crossover study was performed throughout a 24-month period in five children with XLH, each patient serving as his own control. The effect of 12 months of rhGH therapy on height, mineral metabolism, glucose and lipid metabolism, hemoglobin, thyroid and parathyroid function, serum 1,25-(OH)2 vitamin D, osteocalcin, growth hormone, urinary calcium, phosphate, nephrocalcinosis, renal function, and bone density was compared with the effects of 12 months of placebo administration on the same parameters. Results. The average age (mean ± SEM) of the patients at the start of the study was 5.6 ± 1.4 years. Growth hormone therapy improved the height standard deviation score (z-score) from a baseline of −2.66 ± 0.21 to −2.02 ± 0.25 and to −1.46 ± 0.28, after 3 and 12 months, respectively. At the start of the control period the heightz-score was −2.27 ± 0.30 compared with −2.22 ± 0.16 after 12 months of placebo administration. The growth velocity standard deviation score was −1.90 ± 0.40 during the 12 months of placebo administration and +4.04 ± 1.50 during the 12 months of rhGH therapy. An increase in serum phosphate from 0.88 ± 0.07 mmol/L to 1.17 ± 0.14 mmol/L and tubular maximum for phosphate reabsorption (TmP/GFR) from 2.12 ± 0.15 to 3.41 ± 0.25 mg/dL, was observed after 3 months of rhGH therapy. However, both serum phosphate and TmP/GFR were unchanged from baseline after 6, 9, and 12 months of rhGH therapy. Neither serum phosphate nor TmP/GFR changed from baseline during the placebo administration. Insulin-like growth factor 1 (IGF-1) increased from 114 ± 25 to 354 ± 51 ng/mL after 12 months of rhGH therapy. Despite the increase in IGF-1 after rhGH therapy, the value did not exceed normal serum concentration. IGF-1 did not change from baseline after 12 months of placebo administration. Neither therapy with rhGH nor with placebo had an effect on glucose and lipid metabolism, hemoglobin, thyroid and parathyroid function, serum 1,25-(OH)2 vitamin D, alkaline phosphatase, osteocalcin, urinary calcium excretion, the grade of nephrocalcinosis, glomerular filtration rate, or urinary albumin excretion. Twelve months of rhGH therapy increased bone mass and width but not density. Twelve months of placebo administration had no effect on bone mass, width, or density. Conclusion. Patients with XLH have an improvement in linear growth and a transient increase in serum phosphate attributable to a transient decrease in urinary phosphate excretion when treated with rhGH." @default.
• W2124542765 created "2016-06-24" @default.
• W2124542765 creator A5000883642 @default.
• W2124542765 creator A5017132742 @default.
• W2124542765 creator A5061493169 @default.
• W2124542765 date "1997-11-01" @default.
• W2124542765 modified "2023-09-27" @default.
• W2124542765 title "The Effect of Recombinant Human Growth Hormone in Children With X-Linked Hypophosphatemia" @default.
• W2124542765 cites W1966917914 @default.
• W2124542765 cites W1971162897 @default.
• W2124542765 cites W1975939208 @default.
• W2124542765 cites W1976542982 @default.
• W2124542765 cites W1999855392 @default.
• W2124542765 cites W2008265415 @default.
• W2124542765 cites W2021006933 @default.
• W2124542765 cites W2024067973 @default.
• W2124542765 cites W2025921008 @default.
• W2124542765 cites W2033503356 @default.
• W2124542765 cites W2039922507 @default.
• W2124542765 cites W2051409766 @default.
• W2124542765 cites W2051524401 @default.
• W2124542765 cites W2076046440 @default.
• W2124542765 cites W2087195745 @default.
• W2124542765 cites W2094616918 @default.
• W2124542765 cites W2100093237 @default.
• W2124542765 cites W2139666748 @default.
• W2124542765 cites W2316811098 @default.
• W2124542765 doi "https://doi.org/10.1542/peds.100.5.879" @default.
• W2124542765 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9346990" @default.
• W2124542765 hasPublicationYear "1997" @default.
• W2124542765 type Work @default.
• W2124542765 sameAs 2124542765 @default.
• W2124542765 citedByCount "54" @default.
• W2124542765 countsByYear W21245427652012 @default.
• W2124542765 countsByYear W21245427652013 @default.
• W2124542765 countsByYear W21245427652014 @default.
• W2124542765 countsByYear W21245427652015 @default.
• W2124542765 countsByYear W21245427652016 @default.
• W2124542765 countsByYear W21245427652017 @default.
• W2124542765 countsByYear W21245427652018 @default.
• W2124542765 countsByYear W21245427652019 @default.
• W2124542765 countsByYear W21245427652020 @default.
• W2124542765 countsByYear W21245427652021 @default.
• W2124542765 countsByYear W21245427652022 @default.
• W2124542765 countsByYear W21245427652023 @default.
• W2124542765 crossrefType "journal-article" @default.
• W2124542765 hasAuthorship W2124542765A5000883642 @default.
• W2124542765 hasAuthorship W2124542765A5017132742 @default.
• W2124542765 hasAuthorship W2124542765A5061493169 @default.
• W2124542765 hasConcept C124490489 @default.
• W2124542765 hasConcept C126322002 @default.
• W2124542765 hasConcept C134018914 @default.
• W2124542765 hasConcept C142724271 @default.
• W2124542765 hasConcept C204787440 @default.
• W2124542765 hasConcept C27081682 @default.
• W2124542765 hasConcept C2776489590 @default.
• W2124542765 hasConcept C2778573388 @default.
• W2124542765 hasConcept C2779952775 @default.
• W2124542765 hasConcept C2781208988 @default.
• W2124542765 hasConcept C2984496839 @default.
• W2124542765 hasConcept C519063684 @default.
• W2124542765 hasConcept C71315377 @default.
• W2124542765 hasConcept C71924100 @default.
• W2124542765 hasConcept C89551170 @default.
• W2124542765 hasConcept C90924648 @default.
• W2124542765 hasConceptScore W2124542765C124490489 @default.
• W2124542765 hasConceptScore W2124542765C126322002 @default.
• W2124542765 hasConceptScore W2124542765C134018914 @default.
• W2124542765 hasConceptScore W2124542765C142724271 @default.
• W2124542765 hasConceptScore W2124542765C204787440 @default.
• W2124542765 hasConceptScore W2124542765C27081682 @default.
• W2124542765 hasConceptScore W2124542765C2776489590 @default.
• W2124542765 hasConceptScore W2124542765C2778573388 @default.
• W2124542765 hasConceptScore W2124542765C2779952775 @default.
• W2124542765 hasConceptScore W2124542765C2781208988 @default.
• W2124542765 hasConceptScore W2124542765C2984496839 @default.
• W2124542765 hasConceptScore W2124542765C519063684 @default.
• W2124542765 hasConceptScore W2124542765C71315377 @default.
• W2124542765 hasConceptScore W2124542765C71924100 @default.
• W2124542765 hasConceptScore W2124542765C89551170 @default.
• W2124542765 hasConceptScore W2124542765C90924648 @default.
• W2124542765 hasIssue "5" @default.
• W2124542765 hasLocation W21245427651 @default.
• W2124542765 hasLocation W21245427652 @default.
• W2124542765 hasOpenAccess W2124542765 @default.
• W2124542765 hasPrimaryLocation W21245427651 @default.
• W2124542765 hasRelatedWork W1693950885 @default.
• W2124542765 hasRelatedWork W1963989624 @default.
• W2124542765 hasRelatedWork W1972131564 @default.
• W2124542765 hasRelatedWork W2071103727 @default.
• W2124542765 hasRelatedWork W2107762597 @default.
• W2124542765 hasRelatedWork W2124542765 @default.
• W2124542765 hasRelatedWork W2130523537 @default.
• W2124542765 hasRelatedWork W2161206964 @default.
• W2124542765 hasRelatedWork W2164287263 @default.
• W2124542765 hasRelatedWork W2414806821 @default.
• W2124542765 hasVolume "100" @default.
• W2124542765 isParatext "false" @default.

• next